Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys Antibodies by Design and JPT Peptide Technologies to Co-Market Products and Services

NEW YORK, April 18 (GenomeWeb News) - MorphoSys' Antibodies by Design division and JPT Peptide Technologies of Germany will co-market their antibody and peptide products and services, the companies said today.


Under the agreement, Antibodies by Design, of Martinsried, and JPT, a subsidiary of Berlin-based Jerini, will offer each other's products and services to customers worldwide, except for Japan.


Antibodies by Design develops monoclonal antibodies, while JPT offer complementary peptide-based services and products.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.